Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
J&J Talc Bankruptcy Plan Appeal Denied
Novo Nordisk Shares Decline Amid Competitive Pressure
Smart Money Is Betting Big In MRK Options
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
What's Going On With Pfizer Stock Thursday?
AC Immune Stock Climbs 7% on FDA Fast Track Status for Alzheimer's Drug
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Pfizer Hemophilia B Gene Therapy Durveqtix Wins EC Authorization
Bristol-Myers Squibb Q2 Earnings Preview: Strong Results on the Back of Legacy Portfolio
Pfizer's Options: A Look at What the Big Money Is Thinking
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Notable Earnings Before Friday's Open
Looking Into Johnson & Johnson's Recent Short Interest
ServiceNow Turns Heads With Impressive Results, Rev Gains on Gen-AI
AbbVie Raises Outlook as New Immunology Drugs Offset Humira Impact
Zoetis Analyst Ratings
US Stocks Suffered a 'Black Wednesday': How to Hedge Risks in Market Turbulence?
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program